Astonea Labs July 24 board meet for FY26 results

What the company has announced

Astonea Labs Ltd has scheduled a meeting of its Board of Directors for July 24, 2026. The key item is the consideration and approval of the audited consolidated financial results for the financial year ended March 31, 2026 (FY26). The company has also flagged a set of corporate actions for board consideration, making the meeting relevant beyond routine results approval.

The update comes through the company’s disclosure to BSE, where it has also reiterated restrictions under its insider trading code. The trading window for dealing in the company’s shares remains shut, and will reopen only after a cooling-off period tied to the results announcement.

Agenda: results, AGM notice, annual report, and corporate actions

Along with the audited consolidated results for FY26, the July 24 meeting agenda includes:

• Notice for the 9th Annual General Meeting (AGM)
• Annual Report for FY 2025-26
• Proposed alterations to the Memorandum of Association (MOA)
• Incorporation of a new subsidiary

These items indicate the board will handle both compliance-related approvals (AGM documentation and annual report) and structural decisions (MOA changes and a new subsidiary). The company has not provided additional numerical guidance on the subsidiary plan in the disclosed information.

Trading window closure: what investors should note

Astonea Labs has stated that the trading window remains closed and will continue to remain closed until 48 hours after the declaration of the consolidated financial results. The company also indicated that the trading window has been closed since April 1, 2026.

Such closures are a standard requirement under the company’s code of conduct for prevention of insider trading, and are generally aligned with SEBI’s compliance expectations for price-sensitive events like annual results.

Why consolidated results are in focus now

While Astonea Labs has already announced its audited standalone financial results for FY26, the consolidated results were pending because the company was awaiting information from an associate company. The July 24 board meeting is positioned as the forum where those audited consolidated numbers are expected to be considered and approved.

For investors tracking annual performance, consolidated results matter because they reflect the group picture rather than only the standalone operations. In this case, the company’s earlier disclosures explicitly noted that consolidation was delayed due to information awaited from an associate.

Revised FY26 filing to BSE after exchange observations

Separately, Astonea Labs has submitted revised financial results for FY26 to BSE. This revised submission followed BSE observations dated June 19, 2026, relating to the company’s initial results filed on May 30, 2026.

The company stated that the standalone financial results were reviewed and approved by the Board and were signed by an authorized director, Mr. Pardeep Dalal, in line with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It also confirmed that there were no changes to the remaining information previously disclosed on May 30, including the XBRL filing.

Auditor commentary: unmodified opinion, internal controls note

For the standalone audited results, Avnish Sharma & Associates issued an unmodified audit opinion. In the same set of disclosures, the statutory auditor also noted that internal financial controls over financial reporting were operating ineffectively as of March 31, 2026.

The independent auditor’s report referenced in the company’s exchange communication also stated that the results are presented in accordance with listing regulations and provide a true and fair view, as per the disclosures.

FY26 standalone performance: revenue up, profit down

Astonea Labs reported that revenue from operations rose 51.3% to ₹147.5844 crore in FY26. The company’s total income for FY26 stood at ₹148.1043 crore, compared with ₹97.7077 crore in the previous year.

Despite the increase in revenue, the company’s net profit after tax declined 15.6% to ₹4.5152 crore for FY26. The company also disclosed total assets of ₹146.26 crore for the year.

Board approvals linked to FY27: RPT limit and auditor appointments

Alongside the standalone results approval, the Board approved an omnibus approval for Related Party Transactions up to ₹34.00 crore for FY27. It also re-appointed Mr. Sahil Malhotra as Secretarial Auditor and Mr. Mukesh Kumar Gupta as Cost Auditor for FY27.

These decisions typically form part of annual governance and compliance planning, particularly as companies prepare for AGM approvals and annual reporting.

Key facts table

Regulatory positioning: large corporate status

In another disclosure, Astonea Labs informed BSE that it does not qualify as a ‘Large Corporate’ under SEBI’s framework for fundraising through debt securities. The company did not provide further numerical thresholds in the disclosed text, but the confirmation signals that the applicable compliance obligations under that specific framework may not apply.

What to watch next

The July 24 board meeting is expected to bring clarity on Astonea Labs’ audited consolidated FY26 numbers, which have been pending due to associate-company information. Investors will also track outcomes relating to the AGM documentation, any MOA changes, and the decision on incorporating a new subsidiary.

The next concrete update should be the board meeting outcome and the exchange filing of the consolidated audited results, after which the trading window is scheduled to reopen following the 48-hour period stated by the company.